What it is: The only naturally occurring cathelicidin in humans, part of the innate immune system's front-line defense against infection, produced by immune cells and skin at sites of injury.
Research suggests: Research demonstrates potent antimicrobial activity, wound healing promotion, immune cell recruitment, and emerging interest in anti-biofilm and anti-cancer mechanisms.
Best for: Immune defense and wound healing researchers
Key thing to know: Functions as both a direct antimicrobial and an immune signaling molecule; naturally produced at sites of infection, making tissue-level context important in research design.
What is LL-37?
LL-37 is a 37-amino-acid cationic peptide , and the only cathelicidin identified in humans. Cathelicidins are a family of host defense peptides that form part of the innate immune system's front-line response to infection and tissue damage. LL-37 is derived from the C-terminal domain of the human protein hCAP18 (human cationic antimicrobial protein 18), which is stored in its inactive pro-peptide form in the granules of neutrophils and is cleaved to release the active LL-37 fragment at sites of infection or injury.
LL-37 is produced by neutrophils, macrophages, natural killer cells, mast cells, and epithelial cells , including skin, lung, and gut epithelium , making it a ubiquitous component of barrier defense. Researchers study it for its direct antimicrobial and antiviral activity, immune coordination functions, wound healing acceleration, biofilm disruption, and its role in respiratory and skin immunity. Deficiency in LL-37 production has been documented in clinical populations with increased infection susceptibility, supporting its physiological relevance as a host defense factor.
How it works.
LL-37 operates through a dual mechanism that makes it uniquely positioned in immune research. First, it functions as a direct antimicrobial agent: its positively charged amphipathic helical structure enables it to bind to and disrupt the negatively charged membranes of bacteria, fungi, and enveloped viruses , essentially punching holes in their protective outer layers. This membrane-disruption mechanism is distinct from antibiotic mechanisms that target specific metabolic pathways, which is why LL-37 retains activity against many antibiotic-resistant organisms.
Second, LL-37 acts as an immunomodulatory signaling molecule: it binds to receptors on immune cells , including formyl peptide receptor-like 1 (FPRL1) , to coordinate the broader immune response. These downstream effects include promotion of macrophage and neutrophil recruitment, modulation of Toll-like receptor signaling (reducing excessive inflammatory responses while maintaining pathogen clearance), and stimulation of keratinocyte migration and angiogenesis to accelerate wound healing.
Think of it as both a front-line fighter that directly eliminates pathogens and a communications officer coordinating the immune system's broader strategy. Research also documents LL-37's ability to disrupt bacterial biofilms , the protective matrix structures that bacteria form to resist antibiotics , making it of particular interest in the context of chronic infection and antibiotic-resistant organisms. Vitamin D directly regulates LL-37 gene expression, which is why Vitamin D deficiency is consistently associated with reduced LL-37 production and impaired innate immune response.
What the research shows.
LL-37 has a substantial basic science and mechanistic evidence base documenting its antimicrobial spectrum, membrane-disruption mechanism, and immunomodulatory receptor interactions across multiple independent research groups. The antimicrobial activity against gram-positive bacteria, gram-negative bacteria, and enveloped viruses is well-characterized in vitro. Biofilm disruption activity has been documented against clinically relevant organisms including Pseudomonas aeruginosa and Staphylococcus aureus.
Human observational research has linked LL-37 deficiency to clinical susceptibility in several contexts: Kostmann syndrome patients (who lack LL-37) suffer from severe oral and respiratory infections; cystic fibrosis patients show impaired LL-37 activity in the lung; and low Vitamin D states , which reduce LL-37 expression , correlate with increased respiratory infection rates. These observations ground LL-37's relevance in genuine human disease contexts.
Interventional clinical trial data for exogenous LL-37 administration is growing but limited. Topical LL-37 has been studied in wound healing and venous leg ulcer trials with encouraging results. Systemic administration research in humans is at an earlier stage, with safety and dosing parameters still being established.
Biomarkers to review first.
Vitamin D is the most important foundational marker for LL-37 research contexts , its deficiency directly suppresses LL-37 gene expression. Inflammatory and immune baseline markers provide additional context.
What it's commonly researched with.
LL-37 is most often studied in the context of broader immune support protocols, alongside other peptides with immunomodulatory and tissue repair properties. These pairings represent what appears in the research literature , not recommendations for use.